Format

Send to

Choose Destination
Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Author information

1
Rheumatology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France.
2
Pulmonology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France.
3
Dermatology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France.
4
Oncology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France.
5
Hematology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France.
#
Contributed equally

Abstract

OBJECTIVES:

To evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response.

METHODS:

This was a single-centre prospective observational study including all cancer patients receiving ICIs. The occurrence of irAEs and tumour response was assessed on a regular basis. Patients who experienced musculoskeletal symptoms were referred to the department of rheumatology for clinical evaluation and management.

RESULTS:

From September 2015 to May 2017, 524 patients received ICIs and 35 were referred to the department of rheumatology (6.6%). All but one of the rheumatic irAEs occurred with anti-programmed cell death protein 1(PD-1)/PD-1 ligand 1(PD-L1) antibodies, with a median exposure time of 70 days. There were two distinct clinical presentations: (1) inflammatory arthritis (3.8%) mimicking either rheumatoid arthritis (n=7), polymyalgia rheumatica (n=11) or psoriatic arthritis (n=2) and (2) non-inflammatory musculoskeletal conditions (2.8%; n=15). One patient with rheumatoid arthritis was anti-cyclic citrullinated peptide (anti-CCP) positive. Nineteen patients required glucocorticoids, and methotrexate was started in two patients. Non-inflammatory disorders were managed with non-steroidal anti-inflammatory drugs, analgesics and/or physiotherapy. ICI treatment was pursued in all but one patient. Patients with rheumatic irAEs had a higher tumour response rate compared with patients without irAEs (85.7% vs 35.3%; P<0.0001).

CONCLUSION:

Since ICIs are used with increasing frequency, knowledge of rheumatic irAEs and their management is of major interest. All patients were responsive either to low-to-moderate doses of prednisone or symptomatic therapies and did not require ICI discontinuation. Furthermore, tumour response was significantly higher in patients who experienced rheumatic irAEs.

KEYWORDS:

arthritis; inflammation; polymyalgia rheumatica; psoriatic arthritis; treatment

PMID:
29146737
DOI:
10.1136/annrheumdis-2017-212257
[Indexed for MEDLINE]

Conflict of interest statement

Competing interests: MB-B reports consulting and advisory boards for BMS and MSD France. AR reports being a member of Global, European and/or French Advisory Board in GU tumours and/or immunotherapy for Pfizer, Novartis, BMS, Roche, Astra Zeneca and MSD and received travel support from Pfizer, BMS, Roche, Astra Zeneca and MSD. SP reports consulting for BMS and travel support from MSD. AP-L has received honoraria and travel support from BMS and MSD. RV reports being one of the investigators for a clinical trial from BMS, consulting and advisory boards for BMS and MSD and travel support from BMS and MSD. All the others authors declared no conflict of interest for this work.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center